Registry update — unassessed
Dasatinib and Quercetin, a Combination of Senolytics to Treat Fibrotic Non-alcoholic Fatty Liver Disease - the TRUTH Study
Trial registry update: COMPLETED. No results reported in the supplied registry record.
RCTRoutine significance
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Apr 15, 2026 · Discovered: Sep 16, 2026 · Assessed: — · Historical research backfill
What it does not prove
- The actual efficacy of the intervention cannot be evaluated because effect size and outcomes are not reported
- Generalisability beyond the biopsy-proven NAFLD population studied is unclear
- Long-term durability or clinical relevance of any fibrosis reduction is not demonstrated
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- —
- Duration
- —
- Population
- Individuals with biopsy-proven NAFLD with fibrosis
- Primary outcome
- Liver fibrosis
- Effect size
- —
- Significance
- Not reported
- Journal
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- Published
- Apr 15, 2026
Sources
Primary source
Recorded source passages
Abstract or registry material supplied for assessment; source version 1. This is not a claim of full-text review.
To examine the effect of dasatinib plus quercetin on liver fibrosis in individuals with biopsy proven NAFLD with fibrosis by performing a double-blind randomized controlled proof-of-principle study
Source versions
Assessment history
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
Sign in to join the discussion.
No comments yet
Be the first to weigh in on this evidence.